Nothing new or surprising that I can see. Potential Distribution deals all across Asia for Meluka Health seems to be the big one to watch out for.
Jenbrook increasing production capability would be good. It's generating revenues, but we will want to see growth both Locally and international markets. The 49% share in NAP offers a launching pad for the full range of products in the US.
- Forums
- ASX - By Stock
- EVE
- Ann: Appendix 4D and Half Year Report
Ann: Appendix 4D and Half Year Report, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.274M |
Open | High | Low | Value | Volume |
0.1¢ | 0.1¢ | 0.1¢ | $12 | 12.38K |
Featured News
EVE (ASX) Chart |